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Peroxisome Proliferator-Activated Receptors (PPARs) are ligand-
dependent transcription factors belonging to the nuclear hormone
receptor superfamily [1]. Three different isoforms, α, β/δ and γ have
been isolated so far, each encoded by a distinct gene. PPARG (MIM#
20601487) generates four mRNAs by alternate splicing and differen-
tial promoter usage that are translated into two proteins, γ1 and γ2
that differ for 28 additional amino acids at the N-terminus of the γ2
protein [2]. The two isoforms have different expression patterns:
PPARγ2 is mostly expressed in adipose tissue, whereas PPARγ1 is
expressed in colon, monocytes/macrophages and at lower levels in
other tissues including muscle and liver. PPARγ integrates the control
of energy, lipid and glucose homeostasis. Moreover, it plays a pivotal
role in adipogenesis and in the differentiation pathways of manyepithelial cells [1–4]. Since PPARG isolation and characterization,
several heterozygous mutations have been described and correlated
with distinct clinical phenotypes [5]. A frameshift mutation in PPARG
exon 3, coding for the DNA binding domain of the receptor, results
into a truncated, inactive form of the protein [6]. Missense and
nonsense mutations at different codons of exons 5 affect the amino
acid residues that contribute to the ligand binding pocket formation
and coactivator recruitment [5]. These mutants have impaired ability
to bind selective agonists, signiﬁcant reduction in transcriptional
activity and some of them exert a dominant negative effect vs. the
wild type receptor [5 and references therein]. Human subjects bearing
some of these loss-of-function mutations present type 2 diabetes and
several features of themetabolic syndrome (such as insulin resistance,
dyslipidemia, and hypertension) accompanied by partial lipodistro-
phy [5]. A single PPARG gain-of-function mutation, P113G, has
been reported. It prevents phosphorylation of the neighbouring
serine 112 by growth factors via the MAP kinases cascade, thus
stimulating receptor activity [7].
Interestingly, some of the PPARG loss-of-function mutations have
been found in sporadic colorectal cancers, linking this gene's
alterations to colon tumorigenesis [6,8]. PPARγ activation in several
tumors and tumor cell lines by speciﬁc agonists results in induction of
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differentiation [9]. PPARγ is, therefore, considered a tumor suppressor
[6,8], a role that has been questioned because of the conﬂicting results
reported [8 and references therein]. In support to the anti-prolifer-
ative function, a new PPARγ isoform lacking the ligand binding
domain has been found in colorectal cancer, shown to interfere with
wild type receptor and to stimulate cell proliferation [10].
In an attempt to correlate PPARG mutations with tumorigenesis,
we screened a series of colorectal cancers and we report here a novel
germline mutation in a patient with late tumor onset, dyslipidemia,
hypertension and high body mass index (BMI) with normal blood
glucose and insulin levels. Family members, tested positive for the
mutation, presented colonic lesions that can evolve with time to
dysplastic polyps along with different arrays of lipid derangements.
This is the ﬁrst PPARG germline mutation, linked to dyslipidemia and
large intestine polyps, without features of type 2 diabetes. These and
other aspects of PPARG structure and function are discussed.
2. Materials and methods
2.1. DNA, RNA extraction and RT-PCR assay
DNA was extracted from tumor tissues and normal matched
mucosa as previously reported [10]. RNA was extracted from tissues
and cell lines by Trizol™ (Invitrogen, Carlsbad, CA). For cDNA
synthesis, random primed double-stranded cDNA was synthesized
using Superscript III (Invitrogen, Carlsbad, CA). The speciﬁcity of each
oligonucleotide pair used was veriﬁed with the BLAST Program,
whereas the ampliﬁcation conditions were experimentally deter-
mined. PCR products were sequenced with the Big Dye Reaction Kit
(Applied Biosystem, Foster City, CA) and a 3100 ABI Prism automated
sequencer (Applied Biosystem, Foster City, CA). To synthesize PPARγ
cDNA by RT-PCR, we used the following primers: PPARγ exon 1
forward: 5′-TCTCTCCGTAATGGAAGA CC-3′; exon 3 reverse: 5′-
GCATTATGAGACATCCCCAC-3′; exon 2 forward: 5′-ACT CAGCTCTA-
CAATAAGCCTCATGAA-3′; and exon 6 reverse: 5′-CTAGTACAAGTCCTT
GTAGATCT-3′. Nucleotide numbering was performed based on the
reference cDNA sequence (GenBank NM_138712.3), where +1
corresponded to the nucleotide A of ATG, the translation initiation
codon. We subdivided the cDNA obtained in two halves, that were
PCR ampliﬁed and automatically sequenced using exon 1–exon 3 and
exon 2–exon 6 oligonucleotide primer pairs, respectively. To conﬁrm
that the mutation detected in the cDNA was present also at the DNA
level, we PCR ampliﬁed and directly sequenced exon 5 from the DNA
extracted from tumor and peripheral blood. The primers used were:
exon 5 forward: 5′-GAATTCCTTAATGATGGGAG-3′; and reverse: 5′-
CAATAAATATTGCCAAGTCG-3′.
2.2. Expression vectors
S289C V290M and PPARγ cDNAs (used as controls) were cloned in
a pcDNA3 based expression vector (Invitrogen, Carlsbad, CA) in-frame
with a 5′-end FLAG epitope. The wild type and S289C mutant cDNAs
were obtained by RT-PCR starting from total RNA extracted from
tumor tissues. The V290M mutant cDNA, kindly provided by Prof.
Chatterjee, V, K. Cambridge, UK, was transferred into the same vector.
The V290M mutant has impaired transcriptional activity and acts as
dominant negative to the wild type receptor [11,12]. The right
insertion was determined by restriction enzyme map and the correct
sequence by automated DNA sequencing of the plasmids.
2.3. Cell lines and transfections
Cos7, NIH-3T3 and LoVo cells (these latter are derived from a
human colorectal carcinoma) were grown in Dulbecco's modiﬁed
Eagle's media supplemented with 2 mM glutamine and 10% fetal calfserum in a 5% CO2 humidiﬁed atmosphere at 37 °C. Cos7 and LoVo
cells were transfected by Lipofectamine 2000 (Invitrogen, Carlsbad,
CA), and NIH-3T3 cells by Fugene 6 (Roche, Mannheim, Germany).
Where indicated, 16 h after transfection, troglitazone (Sigma-Aldrich,
St. Louis, MO) dissolved in dimethylsulfoxide or the vehicle alone was
added at the indicated concentrations and incubated for a further
24 h.
2.4. Transactivation assay
All transfections were carried out with a luciferase reporter gene
under the transcriptional control of the herpes simplex thymidine
kinase (TK) promoter fused to three copies of the PPRE derived from
the Acyl-CoA oxidase gene (PPRE-TK-Luc) [6,10]. Expression vectors
containing 5′FLAG-tagged-PPARγ and mutant cDNAs (50 or 100 ng)
were transfected alone or in combination; ﬁxed amount (250 ng) of
the reporter gene were used in each experiment [10]. In all cases,
200 ng of the CMV-β galactosidase-containing plasmid were cotrans-
fected to normalize for transfection efﬁciency. Forty-eight hours later,
luciferase and β-galactosidase activity were determined on cell
extracts and luciferase was normalized to β-galactosidase.
2.5. Colony-forming efﬁciency assay
The day after seeding, NIH-3T3 cells (105 cells/six-well plate)
were transfected with 2 µg of the empty vector or the PPARγ and
S289C mutant cDNAs containing plasmids by Fugene 6 (Roche,
Mannheim, Germany). The cells were exposed to the Fugene–DNA
complexes for 16–20 h and then split 1:10 in 100-mm plates in the
G418 selection medium (600 µg/ml Geneticin, Invitrogen Carlsbad,
CA). After 15 days, the plates were stainedwith Crystal Violet. Colony-
forming efﬁciency was calculated by dividing the number of colonies
obtained on plates transfected with the various PPARγ constructs by
that obtained with the empty vector [13].
2.6. BrdUrd incorporation
NIH-3T3 were transfected with the various cDNA containing
expression vectors. DNA synthesis was assayed by a 2-h pulse with
100 µM BrdUrd, and incorporation was monitored as reported [14] by
using the in situ cell proliferation kit FLUOS (Roche, Mannheim,
Germany).
2.7. Western blot analysis and antibodies
Western blot analysis was performed as previously reported
[10,15]. Densitometric analysis of the bands and quantitation to β-
actin was carried out (BioRad GS-800 calibrated densitometer;
Hercules, CA). The following antibodies were used: anti-PPARγ raised
against the C-terminus of the protein (sc-7273), anti-p21 (sc-6246),
anti-cyclin D1 (sc-718), anti-PTEN (sc-7974) (Santa Cruz Biotech-
nology, Santa Cruz, CA); anti-COX-2 (1160112), anti-iNOS (160862)
(Cayman Chemical Co., Ann Arbor, MI) anti-p27kip1 (610241), anti-E-
cadherin (610405) (BD Transduction Laboratories, Lexington, KY)
anti-FLAGM2 (F3165), anti-β-actin (A5441) (Sigma-Aldrich, St. Louis,
MO).
2.8. Loss of heterozygosity analysis
Loss of heterozygosity (LOH) was assessed as described, using the
microsatellite markers D31259 and D3S3701, which ﬂank PPARG [16].
Brieﬂy, 100 ng of DNA extracted from colorectal cancers, polyps and
matched normal mucosa was PCR ampliﬁed and the PCR products
were separated on 6% SDS-PAGE. The allele size and relative intensity
were determined by densitometry (BioRad GS-800 calibrated densi-
tometer, Hercules, CA) and analyzed by GeneMapper software version
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three times in independent experiments with different DNA prepa-
ration. Each allele was scored by comparing the ratio of the signal
intensity between the tumor (T) and its corresponding normal tissue
(N). LOH was conﬁrmed if a tumor allele showed at least a 50%
reduction in intensity in tumor tissue with respect to the matched
normal DNA.
2.9. Immunohistochemistry and immunoﬂuorescence analysis
Immunohistochemical analysis on tumors, transitional mucosa
(TM) and distant non-neoplastic mucosa was performed as described
[15]. The antibodies used were: anti-PPARγ (C-terminus) (sc-7273)
(Santa Cruz Biotechnology, Santa Cruz, CA); anti-β-catenin (610153)
anti-E-cadherin (610405) (BD Transduction Laboratories, Lexington,
KY); anti-COX-2 (1160112) (Cayman Chemical Co., Ann Arbor, MI);
anti-CD68 (KP-1) and anti-Ki-67 (30-9) (Ventana Medical Systems,
Tucson, AZ). The brown-stained colour by DAB chromogen was
deﬁned as positive reactivity, and evaluation of stainingwasmade in a
semi-quantitative manner by two independent investigators [15].
LoVo cells were used for immunoﬂuorescence analysis; they were
plated on coversplips and transfected with the various expression
vectors with Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Cover-
slips were washed with PBS, PFA ﬁxed, permeabilized with Triton
X-100, and incubated 1 h with PBS containing 1% vol/vol BSA. The
ﬁxed cells were then stained with anti-FLAG antibodies and revealed
with FITC-conjugated anti-mouse IgG (Sigma-Aldrich, St. Louis, MO).
Nuclei were stained with Hoechst 33258 (Sigma-Aldrich, St. Louis,
MO). Imageswere generatedwith anAxiophotﬂuorescentmicroscope
(Carl Zeiss, Milan, Italy) using 40× and 63× objectives. Images were
processed using KS300 software (Carl Zeiss, Milan, Italy).
2.10. Statistical analysis
For all the experiments reported, data are expressed asmean±S.D.
and are obtained from at least ﬁve independent experiments
performed in duplicate. Differences were assessed by the Student's t
or Mann–Whitney test and considered to be statistically signiﬁcant
with a P value≤0.05.
3. Results
3.1. Identiﬁcation of a novel PPARγ mutation in colorectal cancer
To determine whether PPARγ plays any role in the pathogenesis of
colorectal cancer, we screened a series of ﬁfty sporadic tumors,
selected on the basis of patients' personal and familial history, absence
of such gene mutations as APC, or PPARG altered levels of
expression [10,17]. To search for mutations along the entire PPARG,
we extracted total RNA from tumor tissues, reverse transcribed and
PCR ampliﬁed using as primers oligonucleotides derived from exons 1
and 3, 2 and 6, respectively, of the mature PPARγ1 mRNA [10]. The
ampliﬁed bands were automatically sequenced: in a single patient we
detected a heterozygous 866CNG transversion in exon 5. We then
searched for the mutation directly on the DNA extracted from tumor
tissue and peripheral blood lymphocytes, by amplifying PPARG exon 5
and sequencing the ampliﬁed product. The same heterozygous
transversion was found in both DNAs, indicating that the mutation
is germline transmitted.We ruled out the possibility that the base pair
change found was a DNA polymorphism, because the analysis of more
than 100 chromosomes from healthy individuals did not show the
same DNA variation (data not shown).
The mutation causes a serine to cysteine substitution at position
289 (S289C) of the mature PPARγ1 protein (position S317C of
PPARγ2) (Supp. Fig. S1A). Sequence comparison of this region of the
ligand binding pocket reveals a remarkable amino acid identity acrossspecies as distant as Xenopus laevis and Homo sapiens (Supp. Fig. S1B).
This striking conservation is likely due to the fact that these amino
acids contribute to the ligand pocket formation and expose side-chain
groups to establish and stabilize ligand–receptor interactions. Among
these conserved amino acids, residues 285, 288, 289 and 290 are
invariant in all species analyzed; interestingly, residues 288, 289 and
290 have been reportedly mutated. In particular, mutation P288H is
associated with sporadic colorectal cancers [6]; V290M is a germline
mutation found in a family with early onset type 2 diabetes and
metabolic syndrome [11,12]; the S289C mutation is reported in this
study. Thus, these three amino acids represent a PPARGmutational hot
spot.
3.2. Clinical ﬁndings
The index case, individual I-1, an 80-year-old woman, underwent
surgery for a newly diagnosed colorectal cancer localized at the
proximal colon that was classiﬁed as a moderately differentiated
adenocarcinoma by histological examination. Lymph nodes along the
entire large intestine were invaded and distant metastases detec-
ted only in the liver. The proband referred repeated episodes of
abdominal pain and intestinal dysfunction, occurring for many years
before tumor onset. She also referred long-standing lipid metabolism
derangements associated to a high BMI and hypertension accompa-
nied by normal blood glucose and insulin levels (Table 1). She
underwent chemotherapy following conventional protocols, which
ensured steady general conditions with an acceptable standard of life
for 3 years. CT scan and other tests, repeatedly carried out during the
follow up, did not show involvement of other organs but liver, besides
persistent blood lipid abnormalities. She died at the age of 83 because
of massive liver metastases. Since the mutation is germline transmit-
ted, all available family members were analyzed, after having given
written informed consent (Fig. 1). The clinical and biochemical
ﬁndings along with the mutation status of the tested family members
are summarized in Table 1. Individual II-1, tested negative, does not
show lipid metabolism alterations or overweight. In 2006, a control
colonoscopy ruled out the presence of large intestine lesions.
Individual II-2, tested positive, has elevated blood cholesterol and
LDL cholesterol. In 2004, because of a painful intestinal dysfunction,
she underwent colonoscopy and an aberrant crypt focus in the right
colon was identiﬁed and removed. Four years later, she developed in
the same location a dysplastic polyp removed during colonoscopy. Of
the two children, individual III-2, tested negative, presents no
dyslipidemia nor large intestine lesions as assessed by a control
colonoscopy, whereas individual III-3, lean and apparently in good
health, refuses any laboratory and genetic test. Individual II-3, tested
positive, presents similar blood lipid abnormalities with normal
glucose and insulin levels. In 2002, because of repeated episodes of
abdominal pain associated to intestinal dysfunction, he underwent
colonoscopy that evidenced three dysplastic polyps in the left colon
that were endoscopically removed. A subsequent control colonoscopy
was negative for polyps in the same and other locations. Of the two
children, individual III-5, tested positive and has an altered lipid proﬁle
with no intestinal malfunctioning, probably due to the young age. In
contrast, individual III-4, tested negative and has no lipid or metabolic
alterations. Individual II-4, positive for the mutation, has blood lipid
abnormalities with normal glucose level. In 2005, because of
abdominal pain and intestinal dysfunction, she underwent colono-
scopy that evidenced a polyp in the distal colon that was endoscop-
ically removed. Of the two daughters, individual III-6, negative for the
mutation, has no blood abnormalities or intestinal dysfunction, while
individual III-7 refuses any testing.
The analysis of the present family reveals that the S289C mutation
is germline transmitted. The proband exhibited a proﬁle of altered
lipid metabolism associated with some features of the metabolic
syndrome. However, all tested mutation carriers display a variable
Table 1
Clinical and biochemical characteristics of the family members tested for the mutation.
Family members
Parameters I1 II1 II2 II3 II4 III2 III4 III5 III6 Reference values
PPARG status a 866CNG wt 866CNG 866CNG 866CNG wt wt 866CNG wt
Gender F M F M F F M F F
Age (at presentation) 83⁎ (80) 62 (57) 59 (54) 55 (50) 59 (53) 39 (34) 26 (21) 18 (14) 30 (25)
BMI b 34.5 22 37.1 25 29 23 26 26 23 BMIN30 kg/m2 obese
Glucose 106 80 80 95 95 93 75 91 104 75–110 mg/dl
Insulin 5.3 6 3 4 5 8 4 5 15 2–25 U/l
Impaired glucose tolerance c A A A A A A A A A P/A
Cholesterol 293 176 270 280 210 180 110 210 170 7–200 mg/dl
HDL cholesterol 79 60 83 75 65 95 85 80 70 N45 mg/dl
LDL cholesterol 196 140 160 210 170 122 90 150 130 0–150 mg/dl
Triglycerides 193 135 103 130 140 125 100 120 120 50–150 mg/dl
Hypertension P A A A A A A A A P/A
Large intestine polyps d 0 0 2 3 1 0 0 0 0 0
Age refers to the current age and in parenthesis that at presentation; Abbreviations: P/A indicates Presence/Absence.
a Nucleotide numbering reﬂects cDNA numbering with +1 corresponding to the A of ATG translation initiation codon in the reference sequence (NM_138712.3). The initiation
codon is codon 1.
b Body mass index (BMI).
c Blood glucose levels measured 2 h after an oral glucose solution administration was b140 mg/dl (b7.8 mmol/l) in all individuals analyzed.
d Reports the results of a control colonoscopy carried out to show the presence/absence of relevant large intestine alterations in family members over 30 years old.
⁎ Denotes a deceased patient.
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insulin sensitivity (Table 1). The occurrence of other metabolic
diseases was ruled out on the basis of blood and clinical tests (data
not shown). Interestingly, family members bearing the mutation
present within their fourth–ﬁfth decade of life intestinal polyps that
presumably can evolve to a full-blown neoplasia, as conceivably
occurred in the index case. The detection of polyps exclusively in
positive-tested family members suggests that the S289C mutation is
transmitted as a dominant trait.
3.3. In vitro expression and transcriptional activity of PPARγ and S289C
and V290M mutants
In order to study the expression of the S289C mutant in an in vitro
system, we transiently transfected the expression vectors containing
the tagged PPARγ, S289C and V290M cDNAs into Cos7 cells
(Supp. Fig. S2A). Using the anti-FLAG antibody we detected a speciﬁc
band of about 64 kDa only in extracts from transfected cells. The
intensity of the wild type band was equivalent to the mutant
bands, as determined after normalization for transfection efﬁciency
(Supp. Fig. S2B).
To evaluate the transactivation capacity of wild type PPARγ,
S289C and V290M mutants, Cos7 cells were cotransfected with theFig. 1. Patient pedigree shows the distribution of the S289C germlinemutation in familymem
crossed symbols deceased individuals; P and C denote the age at diagnosis of individuals bexpression vectors carrying the corresponding cDNAs and a reporter
gene (Fig. 2). This construct contains three copies of a Peroxisome
Proliferator Response Element (PPRE) fused upstream to the minimal
herpes simplex thymidine kinase (TK) promoter that in turn drives
transcription of a luciferase reporter gene [10]. The cells were
transfected for 24 h and exposed to increasing concentrations of
troglitazone, a selective agonist, member of the tiazolidinedione
family of antidiabetic drugs.
In PPARγ-transfected cells, we observed a strong ligand-depen-
dent transcriptional response, whereas in cells transfected with the
S289C and V290Mmutants we observed a negligible response, even at
the highest ligand concentrations used. Indeed, in S289C mutant-
transfected cells we detected an even lower (∼50%) luciferase activity
than in cells transfected with the empty expression vector, which
probably reﬂects inhibition of the endogenous receptor (Fig. 2A, inset)
[11,12]. We also transfected Cos7 cells with the PPRE-TK-luciferase
reporter gene and increasing amounts of PPARγ or mutant expression
vectors, in the presence of a ﬁxed concentration of the ligand (1 µM
troglitazone). PPARγ caused a proportional increase of luciferase
activity, whereas the mutants did not, even at the highest ratios used
(Fig. 2B). Similar effects were obtained with other PPARγ agonists
such as: pioglitazone, rosiglitazone and 15-prostaglandin J2 (15-PGJ2)
(data not shown). Therefore, the S289C mutant does not promotebers. Dots indicate individuals tested for themutation; ﬁlled symbols mutation carriers;
earing large intestine polyps or carcinoma, respectively.
Fig. 2. S289C and V290M mutants have impaired transactivation ability and interfere with PPARγ function. (A) S289C and V290M do not activate a reporter gene. Cos7 cells were
transfected with the PPRE-TK-luciferase reporter gene and PPARγ ( ), S289C (▴), V290M (●) expression vectors or the empty vector ( ), in the presence of increasing
concentrations of troglitazone. Transcriptional activity is reported relative to the maximum obtained with PPARγ. Inset: basal transcriptional activity (see text). (B) Cos7 cells
exposed to a single dose of troglitazone were transfected with the reporter gene and increasing amounts of PPARγ (light grey), S289C (black) or V290M (dark grey) expression
vectors. The reporter/expression vector ratios used are indicated, whereas the transactivation activity is reported relative to the maximum (100%) obtained with PPARγ receptor.
(C) Both mutants interfere with the transactivation activity of PPARγ. The reporter gene was cotransfected with equal amounts of PPARγ and S289C (black) or V290M (dark grey)
expression vectors (ratio1:1) or with PPARγ expression vector alone (light grey) in Cos7 cells exposed to increasing concentrations of troglitazone as indicated. Transcriptional
repression is reported relative to the maximal activation obtained with PPARγ receptor. (D) Cos7 cells, exposed to vehicle or troglitazone, were cotransfected with the reporter
gene and a ﬁxed amount of PPARγ and increasing concentrations of S289C or V290M expression vectors. Re-addition of the wild type PPARγ expression vector recovered
transcriptional activity (lanes indicated as 2:5 and 4:5). Transcriptional repression is reported relative to the maximal activation obtained with PPARγ expression vector alone. The
CMV β-galactosidase control plasmid was added to each cotransfection to normalize for different transfection efﬁciency. Results are the mean±S.D. of at least ﬁve independent
experiments, each performed in duplicate. The P value was calculated for each panel by the Student's t test. *P≤0.05; **Pb0.01 compared to the corresponding controls.
Abbreviation: V = empty vector.
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investigate the possibility that the S289C mutant could interfere
with PPARγ activity, we cotransfected Cos7 cells with the PPRE-TK-
luciferase reporter gene and equal amounts of PPARγ and S289C
expression vectors (ratio 1:1) in the presence of increasing concen-
trations of troglitazone. At all ligand concentrations, luciferase activity
was markedly lower (∼60% of the PPARγ-induced response) than
reporter gene cotransfected with PPARγ expression vector alone; at
the basal level, only minimal differences were instead observed
(Fig. 2C). A similar degree of interference has been reported for
previously described PPARG mutants, such as V290M, and attributed
to a dominant negative mode of action [11,12]. Indeed, in the same
experimental conditions, the V290M mutant reduced wild type
activity as the S289C mutant (Fig. 2C). We also tested S289C and
V290Mmutants' ability to inhibit wild type PPARγ in cells transfected
with ﬁxed amounts of the reporter gene and PPARγ expression vector
along with increasing concentrations of S289C or V290M cDNA
containing vectors. Addition of the mutants proportionally reduced
luciferase activity, whereas re-addition of the wild type receptor
reverted the inhibition observed, suggesting that the mutant receptor
can be titrated out (Fig. 2D). These experiments demonstrate that the
S289C mutant interferes with the transactivation properties of PPARγ
in a ligand-dependent manner.3.4. Growth inhibitory effects of PPARγ and S289C mutant
We wondered whether the S289C mutant retains the ability of the
wild type receptor to inhibit cell growth [8,18,19]. To address this issue,
we used the colony-forming efﬁciency assay [13] using NIH-3T3 cells as
recipients because they express PPARγ at levels below the detectable
threshold of the currently available methods. PPARγ reduced colony-
forming efﬁciency by about 50% with respect to the cells transfected
with the empty vector alone. The S289C mutant, on the contrary,
increased this value by about 50% compared to the control (Fig. 3A).
These experiments indicate that PPARγ inhibits cell growth, while
S289C has lost this property. To determine the impact of the mutant on
cell proliferation,we examined BrdUrd incorporation in cells transiently
expressing PPARγ or the S289C mutant constructs [14]. PPARγ reduced
cell proliferation by about 50% (15% vs. 28%), whereas, surprisingly, the
S289C mutant increased BrdUrd incorporation with respect to the
control (58% vs. 28%) (Fig. 3B). These experiments suggest that the
S289C mutant has lost growth suppression properties.
3.5. The S289C mutant affects target genes expression in vivo
To examine the effects of the S289C mutation on PPARγ activity
and target genes expression in vivo, wemeasured its protein levels on
Fig. 3. S289C and V290M mutants affect PPARγ growth inhibitory ability in vitro. (A) A
colony-forming efﬁciency assay was performed in NIH-3T3 transfected with the
indicated expression vectors (see Section 2). (B) Percentage of BrdUrd incorporating
NIH-3T3 cells transfected with the various expression vectors. The histograms
represent the mean±S.D. of ﬁve independent experiments, each performed in
duplicate. The P value reported in each graph was obtained by the Mann–Whitney
test. Abbreviation: V = empty vector.
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analysis included several specimens on the basis of absence of PPARG
mutations, availability of tissue samples and PPARγ expression levels.
Among the PPARγ target genes, we investigated PTEN and E-cadherin,
both tumor suppressor genes [20,21], and report representative
results on samples with high (2 N–2 T and 3 N–3 T) or low (4 N–4 T)
PPARγ levels, respectively. In the proband, PPARγ showed equivalent
expression in both tissues. PTEN and E-cadherin declined from the
normal mucosa to the tumor, reﬂecting PPARγ activity. In patients 2
and 3 PPARγ expression was higher in tumor than the adjacent
mucosa [22] similarly to PTEN and E-cadherin. PPARγwas low in both
tissues of patient 4 (Fig. 4A), paralleling PTEN and E-cadherin
(Fig. 4B). The expression of several PPARG target genes, such as p27,
p21 and Cyclin D1, mirrored that of PTEN and E-cadherin and was
strictly related to PPARγ expression and activity (data not shown).
Similar results were also obtained in transfections of human colon
carcinoma cells in culture with the wild type and mutant PPARG
expression vectors (HT29 cells, our data not shown). All together
these data demonstrate that the S289C mutant no longer transacti-
vates target genes in vivo, reproducing the results obtained in vitro.3.6. PPARG LOH analysis
To establish whether a somatic “second hit” has occurred in the
proband's tumor tissues, leading to inactivation of the PPARG wild
type allele, we performed LOH analysis, using two microsatellite
markers ﬂanking the 5′ and 3′ ends of the gene [16]. We did not detect
allelic loss in tumor tissues as compared to the normal mucosa (Fig. 4,
panel C). Similarly, no LOHwas detected in the adenoma of individual
II-2 bearing the mutation (data not shown). We did not detect PPARG
LOH also in a subset of sporadic colorectal cancers with reduced
PPARγ expression (Fig. 4, panel C), suggesting that epigenetic
mechanisms could play an important role in PPARG inactivation
(our unpublished data).3.7. Anti-inﬂammatory and anti-proliferative potential of wild type and
S289C PPARγ mutant in vivo
PPARγ interferes with the expression of pro-inﬂammatory genes,
a process termed transrepression [23]. To verify whether our mutant
still exerts this function, we monitored COX-2 and iNOS protein
levels on extracts from the same tumor specimens and matched
adjacent mucosa reported above. In the proband, COX-2 and iNOS
were unexpectedly expressed in the normal mucosa and their levels
increased in the tumor. In patients 2 and 3, their expression was
instead very low. In patient 4, COX-2 and iNOS were higher in the
tumor than the normal mucosa (Fig. 4A and B). As in the proband's
tissues these protein levels were in an inverse relation with PPARγ
activity, we suggest that the mutant receptor no longer impedes the
activation of inﬂammatory genes. To exploit the possibility that
S289C could also affect the proliferation rate of colonic cells and
counteract the inﬂammatory immune response, we analyzed the
same tumor tissues and the paired transitional mucosa by immuno-
histochemistry for Ki-67 and CD68, markers of cell proliferation and
elicited immune response, respectively [24,25]. In the proband's
normal mucosa, the staminal cells and those undergoing proliferation
at the lower third along the longitudinal axis of each crypt showed
positivity for Ki-67 antibody (Fig. 5, panel a). In the transitional
mucosa, i.e. the normal matched mucosa more proximal (only 3 cm
away) to the tumor [26], Ki-67 positive cells were unexpectedly
higher and distributed along the entire longitudinal axis (panel b).
They further increased in tumor sections, where the crypts were no
longer recognizable (panel c). In the same samples, CD68 inﬁltration
proportionally increased from the normal to the transitional mucosa
up to the tumor (panels d–f). In patient 2's sections, the few Ki-67
positive cells showed no differences in the distribution between the
normal and transitional mucosa; they slightly increased only in the
tumor (panels g–i). A similar staining pattern was obtained with the
anti-CD68 antibody (panels j–l). The increased number of the Ki-67
positive cells in the proband's transitional mucosa suggests that they
may have a higher proliferative potential. To verify this hypothesis,
we analyzed bioptic specimens from amutation carrier, individual II-2
(see Table 1), who developed subsequent lesions in the proximal
colon in the last few years (Supp. Fig. S3). The ﬁrst specimen
(P1, panels b1–b3) evidenced an aberrant crypt focus characterized by
a far higher number of Ki-67 and CD68 positive cells than the normal
mucosa (NM, panels a1–a3). Interestingly, 4 years later, she devel-
oped a dysplastic polyp in the same location with a more pronounced
inﬂammation and an even higher number of Ki-67 positive cells
(P2, panels c1–c3).
All together, the data demonstrate that the S289Cmutant is greatly
impaired in activating target genes, in repressing the inﬂammatory
response and in blocking cell proliferation also in vivo. In addition, the
expression proﬁle detected was very different from that observed in
unrelated sporadic and FAP polyps (Supp. Table 1). These we believe
may represent the ﬁrst events that trigger tumorigenesis, as suggested
by the data obtained on tissue specimens from a mutation carrier. In
fact, an aberrant crypt focus can evolve to a dysplastic polyp and,
eventually, to a frank carcinoma if not properly diagnosed and sur-
gically removed. This series of alterations may conceivably have
occurred also in the proband.
3.8. Putative effects of the S289C mutation on the structure of the PPARγ
ligand binding domain
To elucidate the structural basis of the deleterious effects of the
S289C mutation, we examined the crystal structure of both unbound
and ligand-bound form of PPARγ ligand binding domain (PDB code
1PRG and 1FM9, respectively). This domain consists of 12 α-helices
and 4 small β-strands that fold to generate a large hydrophobic cavity
in the form of a helical sandwich where the ligand accommodates
Fig. 4. PPARγ and target gene expression in vivo and LOH analysis. (A) Protein extracts from tumor tissues (T) and matched adjacent mucosa (N) were analyzed by Western blot,
using the antibodies raised against the proteins indicated on the side. Panels illustrate the results obtained with the proband (1*) and some representative samples (from 2 to 4), as
indicated in the text. Them.w. of the proteins investigated are also illustrated. (B) The histograms report the quantitation obtained after densitometric scanning of the bands referred
to β-actin as internal control. Results are reported asmean±S. D. of at least ﬁve independent experiments. The P value was calculated for each panel by the Student's t test. *P≤0.05;
**Pb0.01 compared to the corresponding control tissues. Abbreviation: NS= not signiﬁcant. (C). LOH assay. Bothmicrosatellite loci ﬂanking PPARγwere retained in the tumor tissue
of the proband (1*) as compared to the normal mucosa. No LOH was observed in unrelated tumor samples with low PPARγ expression levels.
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part of the pocket together with helices 2 and 4. When a TZD ligand is
present, the Ser289-OH group forms a direct hydrogen bond with the
head group of the agonist (rosiglitazone in this case), stabilizing
receptor–ligand interactions. The replacement of the serine with a
cysteine residue should not impede the entry and positioning of theFig. 5. Ki-67 and CD68 immunohistochemical analysis of tumor samples from the proband
adjacent normal mucosa (NM), transitional mucosa (TM) and tumor mass (T) from the proagonist, because the size of the cysteine side-chain is similar to that of
the serine and should not impair the formation of a weak hydrogen
bond by means of the SH group (Fig. 6A). Our data, however, indicate
that the transactivation potential of the mutant is dramatically
hampered and is not reverted by the ligand. Other reasons should
be taken into account to explain the low afﬁnity of the mutant proteinand an unrelated patient. (A) The analysis was carried out on 4 µm tick sections of the
band (1*) and individual 2, expressing high levels of wild type PPARγ.
Fig. 6. Effects of the S289C mutation on the structure of the ligand binding pocket. (A). Ribbon representation of PPARγ fold. The rosiglitazone ligand is drawn in ball-and-stick
representation and coloured in blue. (B) Enlargement of the PPARγ ligand binding region. Cys285, Cys289 and Val290 are drawn in ball-and-stick representation. The relative
orientation of the V290 and S289 with respect to the α helix structure is reported, as well as the relative position and vicinity of the two SH groups (285 and 289). The ﬁgures were
prepared with MOLSCRIPT.
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helix 3 that, upon binding, becomes packed against helix 12, providing
the “lid” in the mouse trap model of receptor-agonist binding [27,28].
Moreover, the folding back of helix 12 causes the exposure of the
LXXLLmotif involved in coactivator recruitment. A perturbation in the
interaction between helix 3 and helix 12 could, thus, signiﬁcantly
affect receptor functions. This is indeed modiﬁed when valine 290 is
replaced with methionine. The relative orientation of these two
helices is changed, compromising both receptor-ligand binding and
-coactivator recruitment [11]. Ser289, in contrast, has a different
orientation, which lines the binding pocket for the ligand, so that the
S289C mutation should not affect the interaction between helix 3 and
helix 12 [27,28] (Fig. 6A). Inspection of the region surrounding S289
suggests another intriguing possibility. It is, in fact, tempting to
speculate that the mutant S289C could form a disulphide bridge with
the nearby residue C285 (Fig. 6B). The Cα–Cα distance between these
two residues is indeed in the range of the most common distances
between two Cα of cysteines involved in disulphide bridges [29].
Moreover, in a signiﬁcant number of cases, three amino acid residues
separate the two cysteines involved in disulphide bridges as in the
case reported here [29,30]. The formation of such a bridge in the
binding pocket would render sterically impossible the entrance of the
agonist (i.e. the presence of a rigid covalent link between C285 and
C289 would entirely modify the size and shape of the binding pocket).
This seems to be a reliable structural explanation of the biological
effects caused by the S289C mutation.
3.9. Subcellular localization of the S289C mutant in vitro and in vivo
In order to get further information on the subcellular localization
of PPARγ and its mutants, we transiently transfected the PPARγ,
S289C and V290M cDNAs containing expression vectors into human
colorectal cancer cells (LoVo) and detected the resulting proteins by
immunoﬂuorescence with an anti-FLAG antibody (Supp. Fig. S4A). In
the absence of ligand, the wild type receptor showed a diffuse
cytosolic staining with some positive nuclei (panels a–a1). In contrast,
both mutants were distributed exclusively into the cytosol (panels b
through c1). Upon troglitazone addition, PPARγ showed a markednuclear positivity, (panels e–e1) whereas the S289C mutant a
persistent cytosolic staining (panels b–b1) and the V290M mutant
only a marginal translocation to the nucleus (panels g–g1). We
investigated PPARγ localization in vivo on tissue sections from the
proband and other selected patients (Supp. Fig. S4B). In the normal
mucosa, PPARγ was mainly in the cytosol of cells located at the tip of
the crypts, indicating that it is expressed in fully differentiated cells
(panel a1). In the tumor, PPARγ staining was still conﬁned to the
cytosol (panel a2). In patient 2's normal mucosa, PPARγ was
predominantly nuclear (panel b1); in the tumor, a stronger positivity
was detected and distributed between the cytosol and the nucleus
(panel b2). These data indicate that PPARγ shuttles between the
cytosol and nucleus and addition of the ligand triggers nuclear
translocation. This occurs only partially for the V290M mutant as it
can weakly bind the ligand and restores some biological activities
[11]. The S289C mutant, in contrast, retains a steady and exclusive
cytosolic distribution, probably because it cannot bind the ligand. This
impairment could explain its subcellular localization and at least some
of the results obtained.
4. Discussion
Nuclear receptors play important roles in the establishment and
maintenance of whole-body homeostasis. They, in fact, respond to
several nutritional or exogenous compounds and, at the same time,
control the expression of a variety of genes that regulate a vast array of
metabolic pathways. Among nuclear receptors, PPARs are master
regulators of energy, lipid and carbohydrate metabolism. PPARγ, in
addition, modulates differentiation of several epithelial cells, espe-
cially those of the gastro-intestinal tract where it also contributes to
the control of local inﬂammatory processes [31]. Coherent with these
functions, changes in PPARγ activity have been related to an altered
differentiation process and hence to proliferation and tumorigenesis.
Contrasting reports in the literature, however, have raised the
question whether PPARγ acts as tumor suppressor or stimulates
tumor formation. We report here a novel heterozygous PPARG ger-
mline mutation (c.866CNG) in exon 5, that replaces the amino acid
serinewith cysteine (S289C). Themutant has impaired transactivation
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receptor, as many PPARG loss-of-function mutants previously de-
scribed [5]. Strikingly, the base pair change is found in a patient affected
by colorectal cancer in the proximal colon that invaded lymph nodes of
the entire intestine and produced metastases to the liver. We exclude
that such an association is merely accidental due to the age of the
patient, as a survey of all available family members shows that only
mutation carriers develop speciﬁc lesions of the large intestine in
their fourth–ﬁfth decades of life (Fig. 1 and Table 1). In fact, bioptic
specimens from a mutation carrier show an aberrant crypt focus, the
earliest lesion that initiates colon tumorigenesis, subsequently followed
in the same location by a dysplastic adenomatous polyp with a higher
transforming potential. At the molecular level, these alterations are
characterized by a large number of Ki-67 and CD68 positive cells,
documenting anenhanced proliferation rate and inﬂammatory immune
response. Interestingly, both characteristics are already detected in the
proband's transitional mucosa (Fig. 5), indicating that the mutant
receptor confers a reduced ability to restrain cell growth. Our data
further support the notion that PPARγ is a tumor suppressor. However,
we could not detect loss of the wild type allele in tumor tissues by LOH
analysis (Fig. 4C) or additional somatic mutations (data not shown) at
odds with other tumor suppressors. PPARG somatic heterozygous
mutations (E286P and R288H) have been reported in a series of
colorectal cancers and the profound effects on receptor's activity have
been invoked to explain the association to tumor development [6].
PPARG in vivo could behave either as a haploinsufﬁcient or a dominant
negative tumor suppressor gene, like TP53. [32–34]. However, prelim-
inary data suggest that epigenetic events, such as promotermethylation
and histone modiﬁcations, play an important role in the inactivation of
the wild type allele (our unpublished data) [15].
This is the ﬁrst PPARG germline mutation associated to the
development of large intestine polyp that can putatively evolve to a
full-blown carcinoma, although we do not know the exact frequency
of PPARGmutations, especially those related to colorectal cancer [35].
Another relevant trait associated to the S289Cmutation is the lipid
metabolism derangement. The role that PPARγ plays as a master
regulator of the intermediate metabolism, in adipose tissue differen-
tiation and in skeletal muscle function may explain the systemic
metabolic variations associated with previous PPARGmutations, such
as type 2 diabetes, several features of the metabolic syndrome and
partial lipodystrophy [2–5]. Our proband presented an altered lipid
proﬁle associated with obesity and hypertension without blood
glucose and insulin levels, insulin sensitivity alterations, or lipody-
strophy. Only mutation carriers and no other family members show
different proﬁles of lipid derangement, likely due to a variable
penetrance of the present mutation. In none of the tested individuals,
however, did we detect elevated blood glucose and insulin levels,
altered glucose tolerance test or other signs of type 2 diabetes (Table 1
and Fig.1). The lipid metabolism disturbances present in the S289C
mutation carriers appear then to be distinct from glucose and insulin
metabolism alterations. This is the ﬁrst report of a PPARGmutation in
humans lacking this association and the reasons for such a dis-
crepancy are not known at the moment. Interestingly, mice harboring
a heterozygous Pparg mutation P465L maintain normal glucose and
insulin levels and display no insulin resistance and lipid abnormalities
[36]. The equivalent mutation P467L in humans is characterized by
type 2 diabetes, a severe insulin resistance and a fat distribution
different from that found in mice bearing the same mutation [11,12].
These metabolic differences may be attributed to species-speciﬁc
effects of the mutation. Recently, the same mutant mice have shown
an increased proliferation rate of the neointimal cells that promotes
atherosclerosis [37]. The lack of association with glucose metabolism
alterations and the higher cell proliferation rate are similar to the
features reported here for the S289Cmutation. Finally, superimposing
the S289C mutation to the X-rays crystal structure of the ligand
binding domain suggests that the SH group generated by themutationcould interact with the close cysteine 285-SH group to form an S–S
bridge. The covalent bond would stably reduce the depth of the
binding pocket, impede the positioning of the ligand and could
explain at least in part the biological effects detected.
In conclusion, we report the identiﬁcation of a novel mutation
located in a PPARG mutational hot spot. The S289C mutant is
hampered in its transactivation and transrepression activity and no
longer restrains cell growth. These molecular events may underlie the
lesions found in the colonic mucosa of the mutation carriers and
explain their possible evolution to a frank carcinoma. The mutation
also affects the lipid proﬁle without interfering with the glucose or
insulin metabolism. The similarities and differences in the phenotype
caused by the mutation described here as compared to previously
reported mutations, provide an opportunity to further dissect the role
of PPARγ in various aspects of cellular homeostasis as well as in the
pathogenesis of metabolic diseases and colon tumorigenesis.
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